Mecasermin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Mecasermin
- Mecasermin: From Severe Primary IGF-1 Deficiency (Growth Failure) to Monosomy X (Turner Syndrome)
Mecasermin: From Severe Primary IGF-1 Deficiency (Growth Failure) to Monosomy X (Turner Syndrome)
One-Sentence Summary
Mecasermin is a recombinant human insulin-like growth factor-1 (IGF-1), originally developed for growth failure associated with severe primary IGF-1 deficiency (including growth hormone insensitivity/Laron syndrome). The TxGNN model predicts it may be relevant to Monosomy X (Turner syndrome), but this prediction is currently supported by no clinical trials and no published literature — it rests entirely on knowledge-graph proximity between the growth hormone/IGF-1 axis and Turner syndrome.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in current dataset (data gap — see below) |
| Predicted New Indication | Monosomy X (Turner syndrome) |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 (model prediction only) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed original mechanism of action (MOA) data is not currently available in the evidence pack (data gap). Based on the supporting rationale notes accompanying the predictions, mecasermin is a recombinant human IGF-1, and its core approved use relates to growth failure in severe primary IGF-1 deficiency (including growth hormone insensitivity/Laron syndrome). IGF-1 acts as the principal downstream effector of the growth hormone (GH) axis.
Turner syndrome (monosomy X) is a condition in which growth hormone is already an established treatment for the associated growth failure. Since IGF-1 lies immediately downstream of GH signalling, there is theoretical biological plausibility for a shared growth-axis mechanism. However, this is a mechanistic inference from knowledge-graph proximity rather than a demonstrated pharmacological effect — mecasermin has no trials or publications specifically evaluating its use in Turner syndrome, and the prediction should be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Mecasermin currently holds no marketing authorisation in the UK (market status: Not marketed; 0 authorisations on file). No product, dosage form, or approved-indication data is available for review.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications, and drug-interaction data for mecasermin are currently unavailable in this evidence pack (flagged as a Blocking data gap — TFDA/MHRA product labelling has not yet been sourced or parsed). This gap must be closed before any safety-relevant decision can be made.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate sits at the earliest possible evidence stage (L5, decision stage S0) — the prediction is generated by the TxGNN model alone, with zero supporting clinical trials or literature across all 10 ranked indications in this evidence pack (including monosomy X). Mecasermin is not currently marketed in the UK, and both the mechanism-of-action data and product safety labelling (warnings/contraindications) are missing, which blocks even a preliminary safety assessment.
To proceed, the following is needed:
- Product labelling / SmPC warnings and contraindications (Blocking gap — required before any S1 safety screening)
- Confirmed original approved indication and detailed MOA data, to properly benchmark the repurposing rationale
- A targeted literature and trial-registry search specifically for IGF-1 use in Turner syndrome, rather than relying on KG-derived mechanistic inference alone
- Clinical/endocrinology expert review of the growth-axis rationale (GH used in Turner syndrome vs. IGF-1’s distinct receptor and metabolic effects)
- Should evidence be pursued, note that 9 further candidates in this pack (e.g. Wolman disease, Gaucher disease, oesophageal varices) share the same L5/Hold profile and are lower priority pending the same foundational data gaps
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.